🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Coke zero for the hero ! Rachel Pessah-Pollack, M.D., F.A.C.E.

There are people who believe that you only have two choices for obesity: 1. Diet and exercise Or 2. Drugs and surgery This would be like saying you could only use nails or only use screws for building something. They are not mutually exclusive.

Reserving your incredible artistic skills for the next cover! Thanks for the support Mike Natter, MD

Would be a good read. An area of interest.

Favorite part of #2024ATA - catching up with friends across the 🌎#2024ATA #thyroid @AngelaLeung9 Maria Papaleontiou, MD

Amazing talk! Loved hearing about all the thyroid history that got us where we are today. #2024ATA @AngelaLeung9

There is no shame in taking a medicine for your weight just like there is no shame in taking a medicine for your high blood pressure or depression.

January is #ThyroidAwarenessMonth! 🦋 Dr. Rachel Pessah-Pollack, MD, FACE, shares why thyroid health matters year-round. Let’s raise awareness and support those living with thyroid conditions! Head over to our LinkedIn to see the full quote from Rachel Pessah-Pollack, M.D., F.A.C.E.: shorturl.at/TkSJg

Congratulations!

So honored to receive this promotion. Grateful to my incredible mentors who helped me on this journey. NYU Langone Health Endocrinology Clinical Research NYU Department of Medicine

In those taking tirzepatide in SURMOUNT-1, of the weight lost approximately 75% was fat mass and 25% was lean mass. This degree of lean mass loss is consistent with other medications. Tirzepatide was not associated with a proportionally greater loss of lean tissue in older

Switching to #tirzepatide was superior to increasing to dulaglutide 4.5mg a week for both A1c and weight loss:  acpjournals.org/doi/10.7326/AN… Annals of Int Med

Edward Nirenberg 🇺🇦 This is a wild story that anyone interested in or supplementing vitamin D should read — thank you very much for sharing it. Dr. Spencer Nadolsky Karl Nadolsky had a nice pod on the topic last summer w Rachel Pessah-Pollack, M.D., F.A.C.E. podcasts.apple.com/us/podcast/doc…

📢“You want these patients to be as mobile as possible,” said Rachel Pessah-Pollack, M.D., F.A.C.E. from University of Washington. Read more about #osteoporosis in #rheumatoidarthritis Healio Rheumatology 👇 healio.com/news/rheumatol…

Thanks for featuring me in this article. Beyond crucial we prioritize #bone loss prevention! #Health #osteoporosis Healio

The oral non-peptide GLP-1 agonist space is quickly filling up #ADA2025 #ADASciScessions

Tirzepatide in a target emulation trial demonstrates significantly lower MACE (HR 0.8) and all cause mortality (HR 0.6) compared to dulaglutide in T2DM. 🤯 #ADASciSessions #ADA2025

Choice of #GLP1 matters

Non-English language preference linked to significantly lower #CGM prescription rates in #T2D, even among high-risk insulin users (7.6–7.8% gaps) — independent of clinical factors. Those who could benefit most may be missing out. bit.ly/4nqvnCX Rachel Pessah-Pollack, M.D., F.A.C.E. JAMA Network Open

Thanks for having me Doctor Radio. Such interesting listener questions! 📞📻#osteoporosis #bone #exercise